Abstract
Metastasis causes most deaths from colon cancer yet mechanistic understanding and therapeutic options remain limited. Here we show that expression of microRNA (miR)-192 is inversely correlated with metastatic potential of colon cancer cells. Ectopic expression of miR-192 sensitizes colon cancer cells to growth factor deprivation stress-induced apoptosis, whereas inhibition of miR-192 confers resistance. Overexpression of miR-192 inhibits metastatic colonization to the liver in an orthotopic mouse model of colon cancer. Alterations associated with the metastatic phenotype in the primary tumors include increased apoptosis, decreased proliferation and angiogenesis. Further studies indicate that miR-192 downregulates expression of Bcl-2, Zeb2 and VEGFA in vitro and in vivo, which is responsible for enhanced apoptosis, increased expression of E-cadherin and decreased angiogenesis in vivo, respectively. Finally, studies performed on human colonic adenocarcinoma show that expression of miR-192 is significantly reduced in neoplastic cells as compared with normal colonic epithelium. Importantly, there is a significant decrease in miR-192 expression in stage IV tumors when compared with stage I or II lesions. These findings indicate that miR-192 has an important role in colon cancer development and progression. Our studies underscore the clinical relevance and prognostic significance of miR-192 expression in colon cancer. Therefore, a major implication of our studies is that restoration of miR-192 expression or antagonism of its target genes (Bcl-2, Zeb2 or VEGFA) may have considerable therapeutic potential for anti-metastatic therapy in patients with colon cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
Yokota J . Tumor progression and metastasis. Carcinogenesis 2000; 21: 497–503.
Fidler IJ . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458.
Mehlen P, Puisieux A . Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449–458.
Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180–184.
Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003; 10: 722–733.
Meng F, Wu G . The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev 2012; 31: 455–467.
Du T, Zamore PD . Microprimer: the biogenesis and function of microRNA. Development 2005; 132: 4645–4652.
Bartel DP . MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
Lewis BP, Burge CB, Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999–3004.
Zhang B, Pan X, Cobb GP, Anderson TA . microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1–12.
Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755–11760.
Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866.
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012; 11: 4352–4365.
Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS et al. MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 2012; 7: e46743.
Tian Q, Liang L, Ding J, Zha R, Shi H, Wang Q et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One 2012; 7: e48958.
Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 2005; 33: 6566–6578.
Simms N, Rajput A, Sharratt EA, Ongchin M, Teggart CA, Wang J et al. Transforming growth factor-ss suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer 2012; 12: 221.
Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q et al. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res 2011; 71: 234–244.
Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881–889.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425–436.
Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 2012; 3: 560–566.
Liu XQ, Rajput A, Geng L, Ongchin M, Chaudhuri A, Wang J . Restoration of transforming growth factor-beta receptor II expression in colon cancer cells with microsatellite instability increases metastatic potential in vivo. J Biol Chem 2011; 286: 16082–16090.
Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC . IAP regulation of metastasis. Cancer Cell 2010; 17: 53–64.
Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP . MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91–105.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495–500.
Betel D, Koppal A, Agius P, Sander C, Leslie C . Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90.
Korpal M, Lee ES, Hu G, Kang Y . The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910–14914.
Park SM, Gaur AB, Lengyel E, Peter ME . The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894–907.
Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK et al. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996; 271: 17366–17371.
Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S et al. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res 1999; 59: 4725–4731.
Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995; 270: 22044–22049.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336–1338.
Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008; 68: 4221–4228.
Zubeldia IG, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P144. Exp Cell Res 2013; 319: 12–22.
Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296–2302.
Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23–35.
Kriegel AJ, Fang Y, Liu Y, Tian Z, Mladinov D, Matus IR et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 2010; 38: 8338–8347.
Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D . Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438–447.
Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002; 51: 56–59.
Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999; 59: 320–324.
Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L . High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159–165.
Agui T, McConkey DJ, Tanigawa N . Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 2002; 22: 1769–1776.
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949.
Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 2008; 28: 3865–3870.
Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ . Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998; 17: 227–236.
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613.
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep 2012; 27: 1200–1206.
Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17: 7654–7663.
Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875–883.
Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59: 1794–1802.
Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 2011; 30: 1577–1585.
Kang MH, Reynolds CP . Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126–1132.
Moreira JN, Santos A, Simoes S . Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 2006; 1: 217–235.
Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17: 2059–2065.
Tejpar S, Prenen H, Mazzone M . Overcoming resistance to antiangiogenic therapies. Oncologist 2012; 17: 1039–1050.
Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG . Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res 1988; 48: 2469–2474.
Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65: 3716–3725.
Acknowledgements
This work was supported by NIH/NCI funding R01CA140988-01 and Nebraska Department of Health and Human Services (LB506) 2013-40 to JW.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Geng, L., Chaudhuri, A., Talmon, G. et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 33, 5332–5340 (2014). https://doi.org/10.1038/onc.2013.478
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.478
Keywords
This article is cited by
-
Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease
Journal of Genetic Engineering and Biotechnology (2023)
-
Liver metastases
Nature Reviews Disease Primers (2021)
-
Anticancer potential of metformin: focusing on gastrointestinal cancers
Cancer Chemotherapy and Pharmacology (2021)
-
MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway
World Journal of Surgical Oncology (2020)
-
Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer
Virology Journal (2019)